Bladder Cancer

Combining the antibody drug conjugate, enfortumab vedotin (Padcev) with the immune checkpoint inhibitor pembrolizumab (Keytruda) showed encouraging results in patients with locally advanced or metastatic urothelial cancer who were unable to receive cisplatin-based chemotherapy in the first-line setting. Read More ›

Preliminary results also showed encouraging overall survival data, said Arjun V. Balar, MD, Co-Leader of the Genitourinary Cancers Program, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, who presented the results.

Read More ›

The study included 2 main comparisons of adjuvant chemoradiotherapy versus radiation and adjuvant chemoradiotherapy versus chemotherapy alone. The 3-year disease-free survival rate was 68% for adjuvant chemoradiotherapy versus 63% for radiation alone, but this 5% difference was not statistically significant. The 3-year disease-free survival rate in the second comparison was 68% for chemoradiotherapy versus 56% for chemotherapy alone, a numerical trend toward improved survival with chemoradiotherapy.

Read More ›

In the era of personalized medicine, identifying patients with cancer who will benefit most from a specific treatment is the Holy Grail. Currently, there is no test to identify effective chemotherapy before administering treatment. Read More ›

It is valid to predict survival using tumor stage after neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC), said Peter Black, MD, Senior Research Scientist, Vancouver Prostate Centre, British Columbia, Canada. Read More ›

Subscribe to
Urology Practice Management

Stay up to date with urology news & updates by subscribing to recieve the free UPM print publications or weekly e‑Newsletter.

I'd like to recieve: